FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

مكتبة البروتيدات

CJC-1295 (with DAC)

CJC-1295 DAC / Drug Affinity Complex CJC-1295

Growth Hormone Secretagogues

CJC-1295 with DAC (Drug Affinity Complex) is a long-acting synthetic GHRH analog that incorporates a maleimidopropionic acid linker enabling covalent binding to serum albumin, extending its half-life to 6-8 days. Developed by ConjuChem Biotechnologies, it produces sustained elevation of growth hormone and IGF-1 levels from a single weekly injection. It is primarily researched for growth hormone deficiency, muscle wasting, and age-related GH decline.

mechanism of action

Modified GHRH analog conjugated to a Drug Affinity Complex (DAC) that binds serum albumin, dramatically extending half-life. Produces sustained elevation of GH and IGF-1 levels rather than pulsatile release. Continuously stimulates GHRH receptors.

Research Protocols

للاستخدام البحثي فقط. ليس مشورة طبية.

Research protocols use 1-2mg once or twice weekly via subcutaneous injection. The long half-life means GH elevation is sustained, not pulsatile. Less frequent dosing but different pharmacodynamic profile than no-DAC version.

Research Notes

Clinical Research Status

CJC-1295 with DAC reached Phase 2 clinical trials before development was discontinued following a participant death attributed to a myocardial infarction (causality was debated). Published trials demonstrated significant and sustained increases in GH and IGF-1 with weekly or biweekly dosing. The compound remains available through research suppliers despite the halted clinical program.

Key Published Findings

A single 30-60mcg/kg injection produced sustained GH elevation for 6+ days and IGF-1 increases of 1.5-3x baseline lasting up to 2 weeks. The GHRH analog demonstrated dose-proportional pharmacokinetics with predictable IGF-1 responses. Studies showed increases in lean body mass and reductions in visceral fat with repeated administration.

Safety Profile

The sustained GH elevation raises theoretical concerns about prolonged IGF-1 exposure compared to pulsatile protocols. Common side effects include injection site reactions, water retention, paresthesias, and headache. The extended half-life means side effects may persist for days rather than hours, making dose titration more challenging.

Drug Interactions & Contraindications

Same contraindications as the no-DAC variant apply, with additional concern regarding the inability to quickly discontinue effects due to the long half-life. Not recommended in combination with exogenous GH as this may cause excessive IGF-1 elevation. Contraindicated in diabetic patients due to GH's insulin-antagonistic effects at sustained high levels.

Comparison to Related Compounds

The DAC variant provides convenience of weekly dosing but sacrifices the physiological pulsatile GH pattern that the no-DAC version produces. Most researchers now prefer the no-DAC version combined with a GHRP for a more natural GH profile with better safety margins. The sustained elevation from DAC may increase risk of side effects associated with chronic GH excess (joint pain, insulin resistance, fluid retention).

Community Observations

Typically dosed at 1-2mg once or twice weekly via subcutaneous injection. Less popular than the no-DAC variant among experienced users due to concerns about blunted GH pulsatility and potential for desensitization. Some users combine it with GHRPs on non-injection days to maintain pulsatile stimulation alongside the baseline elevation.

Half Life

~6-8 days

Reconstitution

Bacteriostatic water (BAC)

Storage

Lyophilized

Refrigerate 2-8C up to 24 months.

Reconstituted

Refrigerate 2-8C. Use within 30 days.

US Legal Status

Research chemical (not FDA-approved)

Also Known As

CJC-1295 DACDrug Affinity Complex CJC-1295

الأسئلة الشائعة

ما هو CJC-1295 (with DAC)؟

CJC-1295 with DAC (Drug Affinity Complex) is a long-acting synthetic GHRH analog that incorporates a maleimidopropionic acid linker enabling covalent binding to serum albumin, extending its half-life to 6-8 days. Developed by ConjuChem Biotechnologies, it produces sustained elevation of growth hormone and IGF-1 levels from a single weekly injection. It is primarily researched for growth hormone deficiency, muscle wasting, and age-related GH decline.

كيف يعمل CJC-1295 (with DAC)؟

Modified GHRH analog conjugated to a Drug Affinity Complex (DAC) that binds serum albumin, dramatically extending half-life. Produces sustained elevation of GH and IGF-1 levels rather than pulsatile release. Continuously stimulates GHRH receptors.

ما هو الوضع التنظيمي لـ CJC-1295 (with DAC) في الولايات المتحدة؟

Research chemical (not FDA-approved)

ما هو عمر النصف لـ CJC-1295 (with DAC)؟

~6-8 days

ما الأسماء الأخرى لـ CJC-1295 (with DAC)؟

CJC-1295 DAC, Drug Affinity Complex CJC-1295

Peptide Contacts provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.

Read full disclaimer